Comparison of efficacy and safety of early intensive treatment with atorvastatin versus simvastatin in patients with acute coronary syndrome

Objective:To compare the effects and safety of atorvastatin versus simvastatin in early intensive treatment on lipid-lowering and anti-inflammation in patients with acute coronary syndrome (ACS).Method:A total of ninety-two patients with ACS was enrolled and randomized into two groups, including the atorvastatin treatment group (n=47, atorvastatin 40 mg qn) and the simvastatin treatment group ( n=45,simvastatin 40 mg qn).Efficacy and safety were determined by measuring changes of parameters including total cholesterol(TC), low density lipoprotein cholesterol(LDL-C), triglyceride(TG), high density lipoprotein cholesterol(HDL-C), high sensitive C-reactive protein (hs-CRP), alanine aminotransferase (ALT) and aspartate aminotransferase(AST) levels before treatment and at the end of 4 and 8 week after treatment. Main cardiovascular events and drug-adverse reactions were also recorded.Result:①TC、LDL-C、TG、and hs-CRP levels were reduced significantly after 4 weeks or 8 weeks in two groups, and presented no difference between two groups. ②There was no significant difference to therapeutic effect between two groups. ③The main cardio-cerebral vascular events were decreased in two groups and no difference was found between them. ④ Incidence of adverse reactions as influence on liver enzyme was low and no difference was found between two groups.Conclusion:The efficacy of atorvastatin on serum TC,LDL-C, TG and hs-CRP in patients with ACS are the same as those of simvastatin. No differences of therapeutic effect and adverse effects are found between them, suggesting that intensive dose statins is feasible and safe.